Updates are available Correction dated 2022-10-03
Click to view Correction: https://doi.org/10.1007/s00394-022-03006-7
-
Authors
Cano-Ibáñez, Naomi https://orcid.org/0000-0002-3640-5486
Quintana-Navarro, Gracia M. https://orcid.org/0000-0003-4413-4062
Alcala-Diaz, Juan F. https://orcid.org/0000-0002-4572-3611
Rangel-Zuñiga, Oriol A. https://orcid.org/0000-0003-3495-5705
Camargo, Antonio https://orcid.org/0000-0002-0415-4184
Yubero-Serrano, Elena M. https://orcid.org/0000-0002-2733-5359
Perez-Corral, Isabel
Arenas-de Larriva, Antonio P. https://orcid.org/0000-0001-8897-5176
Garcia-Rios, Antonio https://orcid.org/0000-0001-7320-9006
Perez-Martinez, Pablo https://orcid.org/0000-0001-7716-8117
Delgado-Lista, Javier https://orcid.org/0000-0002-2982-2716
Lopez-Miranda, Jose https://orcid.org/0000-0001-9689-5918
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00924937 at ClinicalTrials.govDocuments that mention this clinical trial
Plasma lipidic fingerprint associated with type 2 diabetes in patients with coronary heart disease: CORDIOPREV study
https://doi.org/10.1186/s12933-023-01933-1
CORonary Diet Intervention with Olive oil and cardiovascular PREVention study (the CORDIOPREV study): Rationale, methods, and baseline characteristics
https://doi.org/10.1016/j.ahj.2016.04.011
Changes in quantity plant-based protein intake on type 2 diabetes remission in coronary heart disease patients: from the CORDIOPREV study
https://doi.org/10.1007/s00394-022-03080-x
Long-term effect of a dietary intervention with two-healthy dietary approaches on food intake and nutrient density in coronary patients: results from the CORDIOPREV trial
https://doi.org/10.1007/s00394-022-02854-7
A plasma fatty acid profile associated to type 2 diabetes development: from the CORDIOPREV study
https://doi.org/10.1007/s00394-021-02676-z
Mediterranean Diet Reduces Atherosclerosis Progression in Coronary Heart Disease: An Analysis of the CORDIOPREV Randomized Controlled Trial
https://doi.org/10.1161/strokeaha.120.033214
Sex-specific differences in intestinal microbiota associated with cardiovascular diseases
https://doi.org/10.1186/s13293-024-00582-7
Modulation of circulating levels of advanced glycation end products and its impact on intima-media thickness of both common carotid arteries: CORDIOPREV randomised controlled trial
https://doi.org/10.1186/s12933-024-02451-4
Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study
https://doi.org/10.1186/s12933-021-01260-3
-
Funding
Funding for this research was provided by:
Juan de la Cierva formación programme
Nicolas Monardes programme
Río Hortega programme
Fundacion Patrimonio Comunal Olivarero
Ministerio de Ciencia e Innovacion (AGL2009-122270)
Ministerio de Ciencia e Innovación (PI10/01041, PI13/00023)
Ministerio de Economía y Competitividad (AGL2012/39615)
Consejeria de Salud, Junta de Andalucia (PI0193/09)
consejería de salud, junta de andalucía (PI-0252/09)
Consejería de Salud, Junta de Andalucía (PI-0058/10, PI-0206-2013)
Consejería de Economía, Innovación, Ciencia y Empleo (CVI-7450)
Universidad de Córdoba
- License Information
-
More Information
Article History
Received: 27 September 2021
Accepted: 22 February 2022
First Online: 29 March 2022
Change Date: 3 October 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00394-022-03006-7
Declarations
:
: The authors declare that they have no current or potential conflicts of interest.
: The protocol was written in accordance with the principles of the Declaration of Helsinki. The respective Institutional Review Board (IRB) by the Human Investigation Review Committee of the Reina Sofia University Hospital (Córdoba, Spain) approved the study protocol. The trial was registered in 2009 at ClinicalTrials.gov (number NCT00924937). Recruitment took place from July 2009 to February 2012. All subjects provided written informed consent.
